Discordance of the estrogen receptor and HER-2/neu in breast cancer from primary lesion to first and second metastatic site

Elyse E Lower,1 Shagufta Khan,2 Diane Kennedy,1 Robert P Baughman1 1Department of Medicine, 2Department of Pathology, University of Cincinnati Medical Center, Cincinnati, OH, USA Background: Hormone receptor and HER-2/neu discordance between the primary lesion and first metastasis has been reported...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lower EE, Khan S, Kennedy D, Baughman RP
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	breast cancer estrogen receptor progesterone receptor survival HER-2/neu tumor discordance Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/bb4a4d6d96b44518a29858549827e6a0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:bb4a4d6d96b44518a29858549827e6a0
record_format	dspace
spelling	oai:doaj.org-article:bb4a4d6d96b44518a29858549827e6a02021-12-02T06:02:45ZDiscordance of the estrogen receptor and HER-2/neu in breast cancer from primary lesion to first and second metastatic site1179-1314https://doaj.org/article/bb4a4d6d96b44518a29858549827e6a02017-08-01T00:00:00Zhttps://www.dovepress.com/discordance-of-the-estrogen-receptor-and-her-2neu-in-breast-cancer-fro-peer-reviewed-article-BCTThttps://doaj.org/toc/1179-1314Elyse E Lower,1 Shagufta Khan,2 Diane Kennedy,1 Robert P Baughman1 1Department of Medicine, 2Department of Pathology, University of Cincinnati Medical Center, Cincinnati, OH, USA Background: Hormone receptor and HER-2/neu discordance between the primary lesion and first metastasis has been reported. This study was performed to determine further biomarker discordance rates between the first and subsequent metastatic breast cancer lesions. Methods: We performed a retrospective review of paired biomarkers from primary breast cancers compared to first reported and subsequent metastases from 103 patients with breast cancer. The estrogen receptor (ER), progesterone receptor (PR), and HER-2/neu status were reported at all three time points. In addition, hormone, cytotoxic, and targeted treatments were recorded for primary and metastatic disease, and survival was determined. Results: Between the primary and first metastases, discordance rates for ER, PR, and HER-2/neu were 15.8%, 33.7%, and 14.3%, respectively. There was discordance between the first and second metastases for the ER receptor in 18.8%, PR receptor in 19.8%, and HER-2/neu in 10.7%. Overall, there was discordance between the primary tumor and either the first or second metastases for ER in 27.7%, PR receptor in 40.7%, and HER-2/neu in 19.6% of cases. Discordance of either ER or PR affected survival, with worse survival experienced by those patients with all three hormone receptors remaining negative, and intermediate survival reported for those with discordant tumors (ER χ2=14.27, p=0.0008; PR χ2=11.31, p=0.0035). There was no difference in survival for patients whose HER-2/neu tumors were discordant. Conclusion: This study demonstrated that continued metastatic disease evolution may be associated with different tumor biology and that studies of metastatic lesions appear warranted, especially if targeted therapy is an option. Keywords: breast cancer, estrogen receptor, progesterone receptor, survival, HER-2/neu, tumor discordanceLower EEKhan SKennedy DBaughman RPDove Medical Pressarticlebreast cancerestrogen receptorprogesterone receptorsurvivalHER-2/neutumor discordanceNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast Cancer: Targets and Therapy, Vol Volume 9, Pp 515-520 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	breast cancer estrogen receptor progesterone receptor survival HER-2/neu tumor discordance Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	breast cancer estrogen receptor progesterone receptor survival HER-2/neu tumor discordance Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Lower EE Khan S Kennedy D Baughman RP Discordance of the estrogen receptor and HER-2/neu in breast cancer from primary lesion to first and second metastatic site
description	Elyse E Lower,1 Shagufta Khan,2 Diane Kennedy,1 Robert P Baughman1 1Department of Medicine, 2Department of Pathology, University of Cincinnati Medical Center, Cincinnati, OH, USA Background: Hormone receptor and HER-2/neu discordance between the primary lesion and first metastasis has been reported. This study was performed to determine further biomarker discordance rates between the first and subsequent metastatic breast cancer lesions. Methods: We performed a retrospective review of paired biomarkers from primary breast cancers compared to first reported and subsequent metastases from 103 patients with breast cancer. The estrogen receptor (ER), progesterone receptor (PR), and HER-2/neu status were reported at all three time points. In addition, hormone, cytotoxic, and targeted treatments were recorded for primary and metastatic disease, and survival was determined. Results: Between the primary and first metastases, discordance rates for ER, PR, and HER-2/neu were 15.8%, 33.7%, and 14.3%, respectively. There was discordance between the first and second metastases for the ER receptor in 18.8%, PR receptor in 19.8%, and HER-2/neu in 10.7%. Overall, there was discordance between the primary tumor and either the first or second metastases for ER in 27.7%, PR receptor in 40.7%, and HER-2/neu in 19.6% of cases. Discordance of either ER or PR affected survival, with worse survival experienced by those patients with all three hormone receptors remaining negative, and intermediate survival reported for those with discordant tumors (ER χ2=14.27, p=0.0008; PR χ2=11.31, p=0.0035). There was no difference in survival for patients whose HER-2/neu tumors were discordant. Conclusion: This study demonstrated that continued metastatic disease evolution may be associated with different tumor biology and that studies of metastatic lesions appear warranted, especially if targeted therapy is an option. Keywords: breast cancer, estrogen receptor, progesterone receptor, survival, HER-2/neu, tumor discordance
format	article
author	Lower EE Khan S Kennedy D Baughman RP
author_facet	Lower EE Khan S Kennedy D Baughman RP
author_sort	Lower EE
title	Discordance of the estrogen receptor and HER-2/neu in breast cancer from primary lesion to first and second metastatic site
title_short	Discordance of the estrogen receptor and HER-2/neu in breast cancer from primary lesion to first and second metastatic site
title_full	Discordance of the estrogen receptor and HER-2/neu in breast cancer from primary lesion to first and second metastatic site
title_fullStr	Discordance of the estrogen receptor and HER-2/neu in breast cancer from primary lesion to first and second metastatic site
title_full_unstemmed	Discordance of the estrogen receptor and HER-2/neu in breast cancer from primary lesion to first and second metastatic site
title_sort	discordance of the estrogen receptor and her-2/neu in breast cancer from primary lesion to first and second metastatic site
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/bb4a4d6d96b44518a29858549827e6a0
work_keys_str_mv	AT loweree discordanceoftheestrogenreceptorandher2neuinbreastcancerfromprimarylesiontofirstandsecondmetastaticsite AT khans discordanceoftheestrogenreceptorandher2neuinbreastcancerfromprimarylesiontofirstandsecondmetastaticsite AT kennedyd discordanceoftheestrogenreceptorandher2neuinbreastcancerfromprimarylesiontofirstandsecondmetastaticsite AT baughmanrp discordanceoftheestrogenreceptorandher2neuinbreastcancerfromprimarylesiontofirstandsecondmetastaticsite
_version_	1718400132984078336

Discordance of the estrogen receptor and HER-2/neu in breast cancer from primary lesion to first and second metastatic site

Ejemplares similares